• GENESIS Biomed directly invested €50,000 in Corify Care in this round as a sign of commitment to the project.

• This is the 21st round of funding that the consultancy has helped to close since its founding.

• Corify Care and GENESIS Biomed have been working closely together since their inception.

Corify Care’s mission is to transform the diagnosis and treatment of heart disease, having so far developed a cost-effective non-invasive cardiac mapping tool (ACORYS) to stratify patients and guide arrhythmia ablation. The spin-off was founded in 2019 by María Guillem (UPV), Francisco Fernández-Avilés and Felipe Atienza (the latter two from the Gregorio Marañón Hospital) and has Andreu Climent as CEO.

Last December the company, Corify Care, closed a €6M investment round, combining private funds led by Clave-Mondragón and public funds, with advice from GENESIS Biomed. This financing will allow Corify to expand in Europe and prepare its entry into the US market, with FDA Clearance expected in the coming months. GENESIS Biomed, in addition to advising, also invested €50,000 directly in the round, reaffirming its commitment to the project.

Since its inception, GENESIS Biomed’s collaboration with Corify Care has been an essential pillar throughout the process of founding and consolidating the spin-off. This strategic alliance has allowed Corify to consolidate its position as a leader in medical technology, thanks to the support of GENESIS Biomed in key areas such as fundraising and strategic development.

Key milestones of the collaboration

The relationship between the two companies began in December 2017, when Corify was in its early stages of development. GENESIS Biomed then played a crucial role in the creation of its first business plan and in closing its first round of seed funding, which raised €300,000. Subsequently, GENESIS Biomed contributed to obtaining public funding through projects such as AFFINE, funded by EIT Health with €750,000, and the CDTI Cervera programme, which provided €1 million.

Subsequently, the award of the SAVE-COR project, to which GENESIS Biomed also contributed, and financed by EIT Health, made it possible to validate the clinical efficacy of the ACORYS system, obtain CE marking and validate the business model, a prerequisite for its commercialisation in Europe.

In the field of private financing, GENESIS Biomed’s participation in the two most important investment rounds for Corify, the aforementioned €6M and a previous one in 2021 for €2.35M led by Clave Capital and backed by strategic partners such as the Mondragon Corporation and the CDTI Innvierte programme, should be highlighted. This round allowed progress to be made in the development and validation of ACORYS. In addition, the participation of GENESIS Biomed in the shareholding made it a partner of Corify Care, further strengthened by the participation of the CEO, Josep Lluís Falcó, as a member of the company’s Board of Directors.

Innovation in heart health: ACORYS and beyond

Corify’s ACORYS system represents a disruptive advance in cardiac electrophysiology. Its technology uses 128 sensors to perform real-time global mapping of the heart using 3D reconstruction, enabling faster, more accurate and safer procedure planning and execution. In clinical studies, ACORYS has demonstrated 88.9% efficacy in the ablation of atrial fibrillation, transforming the treatment of arrhythmias.

But innovation does not stop there. In 2022, Corify, with the support of GENESIS Biomed, led the DIGI-Heart project, funded with 300,000 euros by the Ministry of Industry, Trade and Tourism. This project focused on developing a digital mapping tool based on digital heart twins. These virtual models allow predicting cardiac responses and effects to pharmacological treatments or medical devices, offering a new dimension in the personalisation of diagnosis and treatment.

A partnership that leaves its mark

The partnership between GENESIS Biomed and Corify Care is an outstanding example of success in the healthcare sector. “We are proud to have helped turn an innovative vision into a reality that positively impacts the lives of millions of patients,” said Josep Lluís Falcó, founder and CEO of GENESIS Biomed.

With the backing of GENESIS Biomed, Corify Care is poised to lead the global market, bringing its cutting-edge technology to Europe and the United States by 2025.